PharmaEssentia Corporation (LUX:261280523)
Luxembourg
· Delayed Price · Currency is EUR · Price in USD | Market Cap | 7.02B |
| Revenue (ttm) | 424.05M |
| Net Income (ttm) | 136.84M |
| Shares Out | n/a |
| EPS (ttm) | 0.37 |
| PE Ratio | 51.34 |
| Forward PE | 32.22 |
| Dividend | 0.02 (0.09%) |
| Ex-Dividend Date | Aug 11, 2025 |
| Volume | n/a |
| Average Volume | n/a |
| Open | n/a |
| Previous Close | 21.20 |
| Day's Range | n/a |
| 52-Week Range | 13.58 - 24.60 |
| Beta | n/a |
| RSI | 50.81 |
| Earnings Date | Feb 25, 2026 |
About PharmaEssentia
PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint abs for the treatment of solid tumors; P1101 + anti PD-1 for the treatment of hepatocellular carcinoma; and PEG-GCSF for the treatment of neutro... [Read more]
Financial Performance
In 2025, PharmaEssentia's revenue was 15.63 billion, an increase of 60.61% compared to the previous year's 9.73 billion. Earnings were 5.05 billion, an increase of 70.13%.
Financial numbers in TWD Financial StatementsNews
PharmaEssentia Says FDA Accepts SBLA For ET Treatment Ropeginterferon Alfa-2b-njft
(RTTNews) - PharmaEssentia USA Corp., a subsidiary of PharmaEssentia Corp. (6446.TW), on Tuesday said the U.S. Food and Drug Administration has accepted its supplemental Biologics License Application ...
ICC Arbitral Tribunal Rules in Favor of AOP Health in Arbitration Proceedings Pertaining to BESREMi® (Ropeginterferon alfa-2b)
Today, a tribunal under the auspices of the International Chamber of Commerce (ICC) served a partial final award in a dispute between PharmaEssentia Corp. ("PharmaEssentia") and AOP Orphan Pharmaceuti...